Seres Therapeutics to present new post hoc data from SER-155 Phase 1b trial

Seres Therapeutics (MCRB) announced that new post hoc data from its SER-155 Phase 1b trial will be featured in an oral presentation at IDWeek 2025, taking place October 19-22 in Atlanta, Georgia. The presentation will include new data describing differences between the SER-155 and placebo groups in the bacterial and fungal organisms causing BSIs, including BSI event clinical outcomes, antibacterial prophylaxis use, and patterns of antimicrobial resistance among the bacterial BSI organisms.